MedTrace Logo

Risk Assessment Model for Ischemic Stroke Endpoint Events

NCT03174535 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3000

Last updated 2022-04-04

No results posted yet for this study

Summary

The present study aims to develope a risk assessment model of ischemic stroke endpoint events combining multi-dimensional traditional Chinese medicine(TCM) indicators with modern medicine indicators. The proposed study is a registry study based participant survey conducted in 7 hospitals nationwide in China. After obtaining informed consent, a total of 3000 study patients diagnosed with ischemic stroke will be recruited. 1-year follow-ups are carried out on-site in hospitals and by telephone to track endpoint events. At the same time, we conducted a prospective, multicenter, real-world longitudinal cohort study at 7 hospitals in China to investigate the clinical effectiveness of Qilong capsule (QLC) combined with CT for IS with Qi deficiency and blood stasis syndrome.

Conditions

Interventions

DRUG

Qilong capsules (QLC), produced by Jining Huaneng Pharmaceutical Factory Co., Ltd.

The recommended dosage of QLC was 0.4g each time, 3 times a day. The course of treatment was 12 weeks.

Sponsors & Collaborators

  • China Academy of Chinese Medical Sciences

    lead OTHER

Principal Investigators

  • Yanming Xie, M.D. · China Academy of Chinese Medical Sciences

Eligibility

Min Age
35 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-15
Primary Completion
2018-01-31
Completion
2019-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03174535 on ClinicalTrials.gov